Form 8-K aTYR PHARMA INC For: Mar 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
aTyr Pharma (LIFE) PT Lowered to $16 at RBC Capital
March 15, 2024 6:39 AM EDTRBC Capital analyst Kennan MacKay lowered the price target on aTyr Pharma (NASDAQ: LIFE) to $16.00 (from $19.00) while maintaining a Outperform rating.
The analyst comments "From LIFEs YE call, Early Access Program demand underscores the enthusiasm across sites as the ph.III EFZO-FIT... More
